A 6-Week, Multicenter, Rater-Blind, Randomized, Risperidone-Controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia.

Trial Profile

A 6-Week, Multicenter, Rater-Blind, Randomized, Risperidone-Controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Quetiapine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
    • 17 Sep 2012 Results published in the Current Medical Research and Opinion.
    • 14 Jun 2010 Status changed from recruiting to completed added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top